Radiopharmaceutical enhancement by drug delivery systems: A review

Kleynhans, Janke; Grobler, Anne; Ebenhan, Thomas; Sathekge, Mike; Zeevaart, Jan-Rijn

doi:10.1016/j.jconrel.2018.08.008

Cited by 35 publications

(36 citation statements)

References 206 publications

(211 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…To overcome these above limitations, the booming nanoscale drug delivery systems (NDDS) have offered innovative ideas and approaches to fight malignant tumours, exhibiting high antitumour activity and reduced side effects in humans through controlled tumour-oriented drug release [5,6]. Numerous researches indicated that NDDS can reduce drug toxicity, prevent early drug release, protect drugs from rapid blood/renal clearance and achieve the preferential accumulation of drugs within solid tumours with enhanced permeability and retention (EPR) effect [7][8][9][10]. In addition, precise tumour imaging has been recognized to be an important strategy for image-guided cancer treatment.…”

Section: Introductionmentioning

confidence: 99%

Co-encapsulation of magnetic Fe ₃ O ₄ nanoparticles and doxorubicin into biocompatible PLGA-PEG nanocarriers for early detection and treatment of tumours

Liang

Cai

et al. 2019

Artificial Cells, Nanomedicine, and Biotechnology

View full text Add to dashboard Cite

At present, cancer is the first cause of death for humans, but early detection and treatment can help improve prognoses and reduce mortality. However, further development of carrier-assistant drug delivery systems (DDSs) is retarded by the aspects such as the low drug-carrying capacity, carrier-induced toxicity and immunogenicity, complex synthesis manipulation. The development of nanoscale drug delivery systems (NDDS) have been rapidly developed to address these issues. In this article, we used PLGA-PEG with good biocompatibility to encapsulate Fe 3 O 4 nanoparticles (a magnetic resonance imaging contrast agent) and DOX (an antitumour drug) via the emulsion-solvent evaporation method, aimed at achieving a dual function of the early detection and the treatment of mammary cancer. The results showed that the Fe 3 O 4 /DOX/PLGA-PEG nanoparticles had a relatively uniform size, a high carrier rate of Fe 3 O 4 and high encapsulation efficiency of DOX, and a relatively high activity of released DOX within 120 h. In addition, in vitro studies showed that the Fe 3 O 4 /DOX/PLGA-PEG nanoparticles were cytocompatibility in NIH 3T3 fibroblast cells culture study while had a special effect on destroying human breast cancer MCF-7 cells compared with pure DOX solution. In vitro studies revealed that the Fe 3 O 4 /DOX/PLGA-PEG enabled enhanced T2 contrast magnetic resonance. Overall, our multifunctional Fe 3 O 4 /DOX/PLGA-PEG nanoparticles, composed of biocompatible substances and therapeutic/imaging materials, have great potential for the early detection of cancer and accurate drug delivery via the dynamic monitoring using MRI.

show abstract

Section: Introductionmentioning

confidence: 99%

Co-encapsulation of magnetic Fe ₃ O ₄ nanoparticles and doxorubicin into biocompatible PLGA-PEG nanocarriers for early detection and treatment of tumours

Liang

Cai

et al. 2019

Artificial Cells, Nanomedicine, and Biotechnology

View full text Add to dashboard Cite

show abstract

“…Inorganic nanoparticles of lanthanum phosphate containing 225 Ac and monoclonal antibodies for targeting have been optimized to exhibit less isotope leakage and tested for efficacy in vivo. Drug delivery systems for 233 Ra are also under development with different nanoparticle systems like lanthanum phosphate, nanozeolite, hydroxyapatite, and iron oxide nanoparticles 123 . A quantum dot–antibody system comprising Cd 125m Te/ZnS ( t 1/2 , 57.4 days) QD have been shown to accumulate in the lung compared with the spleen and the liver, which has been direct consequence of competitive interaction between vascular and reticuloendothelial systems 124,125 …”

Section: Different Nanoparticle Systems Used For Delivery Of Radiophamentioning

confidence: 99%

Nanoparticulate formulations of radiopharmaceuticals: Strategy to improve targeting and biodistribution properties

Datta

Ray

2020

Labelled Comp Radiopharmac

View full text Add to dashboard Cite

Application of nanotechnology principles in drug delivery has created opportunities for treatment of several diseases. Nanotechnology offers the advantage of overcoming the adverse biopharmaceutics or pharmacokinetic properties of drug molecules, to be determined by the transport properties of the particles themselves. Through the manipulation of size, shape, charge, and type of nanoparticle delivery system, variety of distribution profiles may be obtained. However, there still exists greater need to derive and standardize definitive structure property relationships for the distribution profiles of the delivery system. When applied to radiopharmaceuticals, the delivery systems assume greater significance. For the safety and efficacy of both diagnostics and therapeutic radiopharmaceuticals, selective localization in target tissue is even more important. At the same time, the synthesis and fabrication reactions of radiolabelled nanoparticles need to be completed in much shorter time. Moreover, the extensive understanding of the several interesting optical and magnetic properties of materials in nanoscale provides for achieving multiple objectives in nuclear medicine. This review discusses the various nanoparticle systems, which are applied for radionuclides and analyses the important bottlenecks that are required to be overcome for their more widespread clinical adaptation.

show abstract

“…When a nanosystem acts at the same time as an imaging and therapeutic agent, it is known as a theranostic [53]. The imaging function can be achieved assembling nanosystems attached to radionuclides such as the technetium-99-metastable and other imaging agents which can give real-time information about the function of the nanosystem in the body [54,55].…”

Section: Nanosystemsmentioning

confidence: 99%

The Effect of Nanosystems on ATP-Binding Cassette Transporters: Understanding the Influence of Nanosystems on Multidrug Resistance Protein-1 and P-glycoprotein

Mello

Moraes

Maia

et al. 2020

IJMS

View full text Add to dashboard Cite

The cancer multidrug resistance is involved in the failure of several treatments during cancer treatment. It is a phenomenon that has been receiving great attention in the last years due to the sheer amount of mechanisms discovered and involved in the process of resistance which hinders the effectiveness of many anti-cancer drugs. Among the mechanisms involved in the multidrug resistance, the participation of ATP-binding cassette (ABC) transporters is the main one. The ABC transporters are a group of plasma membrane and intracellular organelle proteins involved in the process of externalization of substrates from cells, which are expressed in cancer. They are involved in the clearance of intracellular metabolites as ions, hormones, lipids and other small molecules from the cell, affecting directly and indirectly drug absorption, distribution, metabolism and excretion. Other mechanisms responsible for resistance are the signaling pathways and the anti- and pro-apoptotic proteins involved in cell death by apoptosis. In this study we evaluated the influence of three nanosystem (Graphene Quantum Dots (GQDs), mesoporous silica (MSN) and poly-lactic nanoparticles (PLA)) in the main mechanism related to the cancer multidrug resistance such as the Multidrug Resistance Protein-1 and P-glycoprotein. We also evaluated this influence in a group of proteins involved in the apoptosis-related resistance including cIAP-1, XIAP, Bcl-2, BAK and Survivin proteins. Last, colonogenic and MTT (3-(4,5-dimethylthiazol-2-yl)- 2,5-diphenyltetrazolium bromide) assays have also been performed. The results showed, regardless of the concentration used, GQDs, MSN and PLA were not cytotoxic to MDA-MB-231 cells and showed no impairment in the colony formation capacity. In addition, it has been observed that P-gp membrane expression was not significantly altered by any of the three nanomaterials. The results suggest that GQDs nanoparticles would be suitable for the delivery of other multidrug resistance protein 1 (MRP1) substrate drugs that bind to the transporter at the same binding pocket, while MSN can strongly inhibit doxorubicin efflux by MRP1. On the other hand, PLA showed moderate inhibition of doxorubicin efflux by MRP1 suggesting that this nanomaterial can also be useful to treat MDR (Multidrug resistance) due to MRP1 overexpression.

show abstract

Radiopharmaceutical enhancement by drug delivery systems: A review

Cited by 35 publications

References 206 publications

Co-encapsulation of magnetic Fe ₃ O ₄ nanoparticles and doxorubicin into biocompatible PLGA-PEG nanocarriers for early detection and treatment of tumours

Co-encapsulation of magnetic Fe ₃ O ₄ nanoparticles and doxorubicin into biocompatible PLGA-PEG nanocarriers for early detection and treatment of tumours

Nanoparticulate formulations of radiopharmaceuticals: Strategy to improve targeting and biodistribution properties

The Effect of Nanosystems on ATP-Binding Cassette Transporters: Understanding the Influence of Nanosystems on Multidrug Resistance Protein-1 and P-glycoprotein

Contact Info

Product

Resources

About

Radiopharmaceutical enhancement by drug delivery systems: A review

Cited by 35 publications

References 206 publications

Co-encapsulation of magnetic Fe 3 O 4 nanoparticles and doxorubicin into biocompatible PLGA-PEG nanocarriers for early detection and treatment of tumours

Co-encapsulation of magnetic Fe 3 O 4 nanoparticles and doxorubicin into biocompatible PLGA-PEG nanocarriers for early detection and treatment of tumours

Nanoparticulate formulations of radiopharmaceuticals: Strategy to improve targeting and biodistribution properties

The Effect of Nanosystems on ATP-Binding Cassette Transporters: Understanding the Influence of Nanosystems on Multidrug Resistance Protein-1 and P-glycoprotein

Contact Info

Product

Resources

About

Co-encapsulation of magnetic Fe ₃ O ₄ nanoparticles and doxorubicin into biocompatible PLGA-PEG nanocarriers for early detection and treatment of tumours

Co-encapsulation of magnetic Fe ₃ O ₄ nanoparticles and doxorubicin into biocompatible PLGA-PEG nanocarriers for early detection and treatment of tumours